Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October

What happened: Sun Pharmaceutical Industries said its board will meet on 12 October 2026 to consider a private placement NCD issue of up to ₹15,000 crore. Key numbers: NCD issue up to ₹15,000 crore. Board meeting 12 October 2026. Reuters reported a nearly $12 billion, 18-month bridge loan for the Organon acquisition. Why it matters: The NCD plan follows reports it would partly fund a bridge loan for the Organon acquisition. Sun Pharma also signed a deal with LIB Therapeutics for lerodalcibep outside the US and China.

Sun Pharmaceutical Industries said its board will meet on 12 October 2026 to consider a private placement NCD issue of up to ₹15,000 crore.

The NCD plan follows reports it would partly fund a bridge loan for the Organon acquisition. Sun Pharma also signed a deal with LIB Therapeutics for lerodalcibep outside the US and China.